Our Commitment to Patients and Beyond: Amgen 2018 Responsibility Highlights Report
June 12, 2019 — Amgen is committed to serving patients with innovative medicines to treat serious diseases. In pursuit of this core mission, we have grown over time from a company with a handful of medicines treating hundreds of thousands of patients largely in the U.S. to a company with 20 medicines treating millions of patients in approximately 100 countries around the world.
Beyond our work to discover, develop and manufacture vital medicines, we are focused on contributing to the greater good in society in numerous ways, which we share in our 2018 Responsibility Highlights Report. We continue to build our Access to Medicine effort, grow the number and reach of science education programs, improve the environmental footprint of our business and create a healthy, inclusive and safe work environment where innovation thrives.
The 2018 Responsibility Highlights Report outlines how Amgen is aligning corporate responsibility efforts with respected international frameworks and includes Amgen’s Communication on Progress associated with the ten principles of the United Nations Global Compact. Additionally, this report discusses the ways in which Amgen aligns with the U.N.’s Sustainable Development Goals.
Some highlights of Amgen’s corporate responsibility program in 2018:
- We donated nearly $100 million worth of Amgen cancer treatments and supportive care medicines for distribution to patients in 18 developing countries at no cost through the nonprofit organization Direct Relief.
- The Amgen Safety Net Foundation provided medicines, with a commercial value in excess of $1 billion, at no cost to patients in the U.S. who could not afford them.
- We achieved our 2020 carbon reduction and water conservation targets ahead of schedule.
- One hundred percent of staff completed Amgen’s Code of Conduct Training.
- We celebrated reaching more than 7 million students through Amgen Foundation’s science education programs.
We are proud to receive external recognition for our efforts. In 2018, Amgen was included on the Dow Jones Sustainability World and North America Indices for the fifth and sixth year in a row, respectively. Amgen earned a perfect score on the 2018 Corporate Equality Index, administered by the Human Rights Campaign Foundation. Additionally, Amgen earned a position on Forbes magazine and Just Capital’s “JUST 100” America’s Most Just Companies listing, among several other prominent recognitions.
The report includes, among other data, environmental sustainability performance data that have been independently verified by Bureau Veritas North America.
For additional information on Amgen’s reporting and Responsibility, see the Letter to Shareholders and Amgen Inc. Annual Report and Responsibility on Amgen.com.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen Media Relations